The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Journal: Evidence-based Cardiology. 2016;9(4): 32‑41

Read: 2674 times

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

. Evidence-based Cardiology. 2016;9(4):32‑41. (In Russ.)

МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Abstract:

Close metadata

References:

  1. Heidenreich P.A., Albert N.M., Allen L.A., et al; on behalf of the American Heart Association Advocacy Coordinating Committee; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Radiology and Intervention; Council on Clinical Cardiology; Council on Epidemiology and Prevention; Stroke Council. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail 2013;6:606—619.
  2. Masoudi F.A., Baillie C.A., Wang Y., et al. The complexity and cost of drug regimens of older patients hospitalized with heart failure in the United States, 1998—2001. Arch Intern Med 2005;165:2069—2076.
  3. Rich M.W. Pharmacotherapy of heart failure in the elderly: adverse events. Heart Fail Rev 2012;17:589—595.
  4. Sturm H.B., Haaijer-Ruskamp F.M., Veeger N.J., et al. The relevance of comorbidities for heart failure treatment in primary care: a European survey. Eur J Heart Fail 2006;8:31—37.
  5. Rushton C.A., Strömberg A., Jaarsma T., Kadam U.T. Multidrug and optimal heart failure therapy prescribing in older general practice populations: a clinical data linkage study. BMJ Open 2014;4:e003698.
  6. Page R.L. 2nd, Lindenfeld J. The comorbidity conundrum: a focus on the role of noncardiovascular chronic conditions in the heart failure patient. Curr Cardiol Rep 2012;14:276—284.
  7. Wong C.Y., Chaudhry S.I., Desai M.M., Krumholz H.M. Trends in co-morbidity, disability, and polypharmacy in heart failure. Am J Med 2011;124:136—143.
  8. Braunstein J.B., Anderson G.F., Gerstenblith G., et al. Noncardiac comorbidity increases preventable hospitalizations and mortality among Medicare beneficiaries with chronic heart failure. J Am Coll Cardiol 2003;42:1226—1233.
  9. Ahluwalia S.C., Gross C.P., Chaudhry S.I., et al. Change in comorbidity prevalence with advancing age among persons with heart failure. J Gen Intern Med 2011;26:1145—1151.
  10. Lang C.C., Mancini D.M. Non-cardiac comorbidities in chronic heart failure. Heart 2007;93:665—671.
  11. Schneider K.M., O’Donnell B.E., Dean D. Prevalence of multiple chronic conditions in the United States’ Medicare population. Health Qual Life Outcomes 2009;7:82.
  12. Goldberg R.M., Mabee J., Chan L., Wong S. Drug-drug and drug-disease interactions in the ED: analysis of a high-risk population. Am J Emerg Med 1996;14:447—450.
  13. Yancy C.W., Jessup M., Bozkurt B., et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013;128:e240—e327.
  14. Green G.A. Understanding NSAIDs: from aspirin to COX-2. Clin Cornerstone 2001;3:50—60.
  15. Feenstra J., Heerdink E.R., Grobbee D.E., Stricker B.H. Association of nonsteroidal anti-inflammatory drugs with first occurrence of heart failure and with relapsing heart failure: the Rotterdam Study. Arch Intern Med 2002;162:265—270.
  16. Heerdink E.R., Leufkens H.G., Herings R.M., et al. NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics. Arch Intern Med 1998;158:1108—1112.
  17. Page J., Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem. Arch Intern Med 2000;160:777—784.
  18. Huerta C., Varas-Lorenzo C., Castellsague J., García Rodríguez L.A. Non-steroidal anti-inflammatory drugs and risk of first hospital admission for heart failure in the general population. Heart 2006;92:1610—1615.
  19. Gislason G.H., Rasmussen J.N., Abildstrom S.Z., et al. Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure. Arch Intern Med 2009;169:141—149. 
  20. Hammill B.G., Curtis L.H., Bennett-Guerrero E., et al. Impact of heart failure on patients undergoing major noncardiac surgery. Anesthesiology 2008;108:559—567. 
  21. Akata T. General anesthetics and vascular smooth muscle: direct actions of general anesthetics on cellular mechanisms regulating vascular tone. Anesthesiology 2007;106:365—391.
  22. Alreja G., Bugano D., Lotfi A. Effect of remote ischemic precondi- tioning on myocardial and renal injury: meta-analysis of randomized controlled trials. J Invasive Cardiol 2012;24:42—48.
  23. Djaiani G.N., Hall J., Pugh S., Peaston R.T. Vital capacity inhalation induction with sevoflurane: an alternative to standard intravenous induction for patients undergoing cardiac surgery. J Cardiothorac Vasc Anesth 2001;15:169—174.
  24. Gupta A., Stierer T., Zuckerman R., et al. Comparison of recovery profile after ambulatory anesthesia with propofol, isoflurane, sevoflurane and desflurane: a systematic review. Anesth Analg 2004;98:632—641.
  25. Landoni G., Bignami E., Oliviero F., Zangrillo A. Halogenated anaes- thetics and cardiac protection in cardiac and non-cardiac anaesthesia. Ann Card Anaesth 2009;12:4—9.
  26. Neuhäuser C., Müller M., Welters I., et al. Effect of isoflurane on echocardiographic left-ventricular relaxation indices in patients with diastolic dysfunction due to concentric hypertrophy and ischemic heart disease. J Cardiothorac Vasc Anesth 2006;20:509—514.
  27. Symons J.A., Myles P.S. Myocardial protection with volatile anaesthetic agents during coronary artery bypass surgery: a meta-analysis. Br J Anaesth 2006;97:127—136.
  28. Lowe D., Hettrick D.A., Pagel P.S., Warltier D.C. Propofol alters left ventricular afterload as evaluated by aortic input impedance in dogs. Anesthesiology 1996;84:368—376.
  29. Bovill J.G. Intravenous anesthesia for the patient with left ventricular dysfunction. Semin Cardiothorac Vasc Anesth 2006;10:43—48.
  30. Lam F., Ransom C., Gossett J.M., et al. Safety and efficacy of dexmedetomidine in children with heart failure. Pediatr Cardiol 2013;34:835—841.
  31. Erdman M.J., Doepker B.A., Gerlach A.T., et al. A comparison of severe hemodynamic disturbances between dexmedetomidine and propofol for sedation in neurocritical care patients. Crit Care Med 2014;42:1696—1702.
  32. Misbin R.I., Green L., Stadel B.V., et al. Lactic acidosis in patients with diabetes treated with metformin. N Engl J Med 1998;338:265—266.
  33. Eurich D.T., Majumdar S.R., McAlister F.A., et al. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care 2005;28:2345—2351.
  34. Masoudi F.A., Inzucchi S.E., Wang Y., et al. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation 2005;111:583—590.
  35. Eurich D.T., McAlister F.A., Blackburn D.F., et al. Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. BMJ 2007;335:497.
  36. Eurich D.T., Weir D.L., Majumdar S.R., et al. Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients. Circ Heart Fail 2013;6:395—402.
  37. American Diabetes Association. Standards of medical care in diabetes–2016. Diabetes Care 2016;39(suppl 1):S60—S71.
  38. US Food and Drug Administration. FDA Drug Safety Communication: FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function. http:// www.fda.gov/downloads/Drugs/DrugSafety/UCM494140.pdf. April 8, 2016. Accessed June 1, 2016.
  39. Delea T.E., Edelsberg J.S., Hagiwara M., et al. Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study. Diabetes Care 2003;26:2983—2989.
  40. Cheng A.Y., Fantus I.G. Thiazolidinedione-induced congestive heart failure. Ann Pharmacother 2004;38:817—820.
  41. Page R.L. 2nd, Gozansky W.S., Ruscin J.M. Possible heart failure exacerbation associated with rosiglitazone: case report and literature review. Pharmacotherapy 2003;23:945—954.
  42. Singh S., Loke Y.K., Furberg C.D. Thiazolidinediones and heart failure: a teleo-analysis. Diabetes Care 2007;30:2148—2153.
  43. Gerstein H.C., Yusuf S., Bosch J., et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial [published correction appears in Lancet. 2006;368:1770]. Lancet 2006;368:1096—1105.
  44. Hernandez A.V., Usmani A., Rajamanickam A., Moheet A. Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and meta-regression analysis of placebo-controlled randomized clinical trials. Am J Cardiovasc Drugs 2011;11:115—128.
  45. Filion K.B., Joseph L., Boivin J.F., et al. Thiazolidinediones and the risk of incident congestive heart failure among patients with type 2 diabetes mellitus. Pharmacoepidemiol Drug Saf 2011;20:785—796.
  46. Loke Y.K., Kwok C.S., Singh S. Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies. BMJ 2011;342:d1309.
  47. Lago R.M., Singh P.P., Nesto R.W. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 2007;370:1129—1136.
  48. Komajda M., McMurray J.J., Beck-Nielsen H., et al. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. Eur Heart J 2010;31:824—831.
  49. Graham D.J., Ouellet-Hellstrom R., MaCurdy T.E., et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA 2010;304:411—418.
  50. Dargie H.J., Hildebrandt P.R., Riegger G.A., et al. A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association functional class I or II heart failure. J Am Coll Cardiol 2007;49:1696—1704.
  51. Giles T.D., Miller A.B., Elkayam U., et al. Pioglitazone and heart failure: results from a controlled study in patients with type 2 diabetes mellitus and systolic dysfunction. J Card Fail 2008;14:445—452.
  52. Deacon C.F., Holst J.J. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety. Expert Opin Pharmacother 2013;14:2047—2058.
  53. Scirica B.M., Bhatt D.L., Braunwald E., et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:1317—1326.
  54. Weir D.L., McAlister F.A., Senthilselvan A., et al. Sitagliptin use in patients with diabetes and heart failure: a population-based retrospective cohort study. JACC Heart Fail 2014;2:573—582.
  55. Monami M., Dicembrini I., Mannucci E. Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 2014;24:689—697.
  56. Jensen G., Sigurd B., Uhrenholt A. Haemodynamic effects of intravenous disopyramide in heart failure. Eur J Clin Pharmacol 1975;8:167—173.
  57. Leach A.J., Brown J.E., Armstrong P.W. Cardiac depression by intravenous disopyramide in patients with left ventricular dysfunction. Am J Med 1980;68:839—844.
  58. Podrid P.J., Schoeneberger A., Lown B. Congestive heart failure caused by oral disopyramide. N Engl J Med 1980;302:614—617.
  59. Echt D.S., Liebson P.R., Mitchell L.B., et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo: the Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991;324:781—788.
  60. Jackson N., Verma S.P., Frais M.A., et al. Hemodynamic dose-response effects of flecainide in acute myocardial infarction with and without left ventricular decompensation. Clin Pharmacol Ther 1985;37:619—624.
  61. Josephson M.A., Ikeda N., Singh B.N. Effects of flecainide on ventricular function: clinical and experimental correlations. Am J Cardiol 1984;53:95B—100B.
  62. Legrand V., Materne P., Vandormael M., et al. Comparative haemodynamic effects of intravenous flecainide in patients with and without heart failure and with and without beta- blocker therapy. Eur Heart J 1985;6:664—671.
  63. Stambler B.S., Beckman K.J., Kadish A.H., et al. Acute hemodynamic effects of intravenous ibutilide in patients with or without reduced left ventricular function. Am J Cardiol 1997;80:458—463.
  64. Pratt C.M., Camm A.J., Cooper W., et al. Mortality in the Survival With ORal D-sotalol (SWORD) trial: why did patients die? Am J Cardiol 1998;81:869—876.
  65. Julian D.G., Prescott R.J., Jackson F.S., Szekely P. Controlled trial of sotalol for one year after myocardial infarction. Lancet 1982;1:1142—1147.
  66. MacNeil D.J., Davies R.O., Deitchman D. Clinical safety profile of sotalol in the treatment of arrhythmias. Am J Cardiol 1993;72:44A—50A.
  67. Hohnloser S.H., Crijns H.J., van Eickels M., et al. Effect of dronedarone on cardiovascular events in atrial fibrillation [published correction appears in N Engl J Med 2011;364:1481]. N Engl J Med 2009;360:668—678.
  68. Hohnloser S.H., Crijns H.J., van Eickels M., et al. Dronedarone in patients with congestive heart failure: insights from ATHENA. Eur Heart J 2010;31:1717—1721.
  69. Køber L., Torp-Pedersen C., McMurray J.J., et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med. 2008;358:2678—2687.
  70. Connolly S.J., Camm A.J., Halperin J.L., et al. Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med 2011;365:2268—2276.
  71. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): ALLHAT Collaborative Research Group. JAMA. 2000;283:1967—1975.
  72. Messerli F.H. Doxazosin and congestive heart failure. J Am Coll Cardiol 2001;38:1295—1296.
  73. Cohn J.N., Archibald D.G., Ziesche S., et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study. N Engl J Med 1986;314:1547—1552.
  74. Walsh R.A. The effects of calcium-entry blockade on left ventricular systolic and diastolic function. Circulation 1987;75(pt 2):V43—V55.
  75. Elkayam U., Amin J., Mehra A., et al. A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure. Circulation 1990;82:1954—1961.
  76. Packer M., O’Connor C.M., Ghali J.K., et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure: Prospective Randomized Amlodipine Survival Evaluation Study Group. N Engl J Med 1996;335:1107—1114.
  77. Packer M., Carson P., Elkayam U., et al. Effect of amlodipine on the survival of patients with severe chronic heart failure due to a nonischemic cardiomyopathy: results of the PRAISE-2 study (Prospective Randomized Amlodipine Survival Evaluation 2). JACC Heart Fail 2013;1:308—314.
  78. The effect of diltiazem on mortality and reinfarction after myocardial infarction: the Multicenter Diltiazem Postinfarction Trial Research Group. N Engl J Med 1988;319:385—392.
  79. Zhang Y., Cheng Z. Sympathetic inhibition with clonidine prolongs survival in experimental chronic heart failure. Int J Cardiol 2000;73:157—162.
  80. Abiuso P., Abelow G. Atrioventricular dissociation in a patient receiving clonidine. JAMA 1978;240:108—109.
  81. van Etta L., Burchell H. Severe bradycardia with clonidine. JAMA 1978;240: 2047.
  82. Cohn J.N., Pfeffer M.A., Rouleau J., et al. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail. 2003;5:659—667.
  83. Swedberg K., Bristow M.R., Cohn J.N., et al. Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failure. Circulation 2002;105:1797—1803.
  84. Franciosa J.A., Jordan R.A., Wilen M.M., Leddy C.L. Minoxidil in patients with chronic left heart failure: contrasting hemodynamic and clinical effects in a controlled trial. Circulation 1984;70:63—68.
  85. Sharkey P.K., Rinaldi M.G., Dunn J.F., et al. High-dose itraconazole in the treatment of severe mycoses. Antimicrob Agents Chemother 1991;35:707—713.
  86. Okamoto J., Fukunami M., Kioka H. Frequent premature ventricular contractions induced by itraconazole. Circ J 2007;71:1323—1325.
  87. Nelson M.R., Smith D., Erskine D., Gazzard B.G. Ventricular fibrillation secondary to itraconazole induced hypokalaemia. J Infect 1993;26:348.
  88. Fung S.L., Chau C.H., Yew W.W. Cardiovascular adverse effects during itraconazole therapy. Eur Respir J 2008;32:240.
  89. Ahmad S.R., Singer S.J., Leissa B.G. Congestive heart failure associated with itraconazole. Lancet 2001;357:1766—1767.
  90. Hauben M., Hung E.Y. A quantitative analysis of the spontaneous reporting of congestive heart failure-related adverse events with systemic anti-fungal drugs. J Clin Pharmacol 2013;53:762—772.
  91. Arsura E.L., Ismail Y., Freedman S., Karunakar A.R. Amphotericin B-induced dilated cardiomyopathy. Am J Med 1994;97:560—562.
  92. Moyssakis I., Vassilakopoulos T.P., Sipsas N.V., et al. Reversible dilated cardiomyopathy associated with amphotericin B treatment. Int J Antimicrob Agents 2005;25:444—447.
  93. Danaher P.J., Cao M.K., Anstead G.M., et al. Reversible dilated cardiomyopathy related to amphotericin B therapy. J Antimicrob Chemother 2004;53:115—117.
  94. Menna P., Paz O.G., Chello M., et al. Anthracycline cardiotoxicity. Expert Opin Drug Saf 2012;11(suppl 1):S21—S36.
  95. Minotti G., Menna P., Salvatorelli E., et al. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004;56:185—229.
  96. Barry E., Alvarez J.A., Scully R.E., et al. Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management. Expert Opin Pharmacother 2007;8:1039—1058.
  97. 97.Von Hoff D.D., Layard M.W., Basa P., et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979;91:710—717
  98. Swain S.M., Whaley F.S., Ewer M.S. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003;97:2869—2879.
  99. Kremer L.C., van Dalen E.C., Offringa M., Voûte P.A. Frequency and risk factors of anthracycline-induced clinical heart failure in children: a systematic review. Ann Oncol 2002;13:503—512.
  100. van Dalen E.C., van der Pal H.J., Kok W.E., et al. Clinical heart failure in a cohort of children treated with anthracyclines: a long-term follow-up study. Eur J Cancer 2006;42:3191—3198.
  101. Ho E., Brown A., Barrett P., et al. Subclinical anthracycline- and trastuzumab-induced cardiotoxicity in the long-term follow-up of asymptomatic breast cancer survivors: a speckle tracking echocardiographic study. Heart 2010;96:701—707.
  102. Colombo A., Sandri M.T., Salvatici M., et al. Cardiac complications of chemotherapy: role of biomarkers. Curr Treat Options Cardiovasc Med 2014;16:313.
  103. Ky B., Putt M., Sawaya H., et al. Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. J Am Coll Cardiol 2014;63:809—816.
  104. Krischer J.P., Epstein S., Cuthbertson D.D., et al. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. J Clin Oncol 1997;15:1544—1552.
  105. Lipshultz S.E., Lipsitz S.R., Mone S.M., et al. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 1995;332:1738—1743.
  106. van Dalen E.C., van der Pal H.J., Caron H.N., Kremer LC. Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy. Cochrane Database Syst Rev 2009:CD005008.
  107. Pinder M.C., Duan Z., Goodwin J.S., et al. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol 2007;25:3808—3815.
  108. Blanco J.G., Sun C.L., Landier W., et al. Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes: a report from the Children’s Oncology Group. J Clin Oncol 2012;30:1415—1421.
  109. Wojnowski L., Kulle B., Schirmer M., et al. NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation 2005;112:3754—3762.
  110. Ryberg M., Nielsen D., Skovsgaard T., et al. Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer. J Clin Oncol 1998;16:3502—3508.
  111. Geiger S., Lange V., Suhl P., et al. Anticancer therapy induced cardiotoxicity: review of the literature. Anticancer Drugs 2010;21:578—590.
  112. van Dalen E.C., Caron H.N., Dickinson H.O., Kremer L.C. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev 2011:CD003917.
  113. Hensley M.L., Hagerty K.L., Kewalramani T., et al. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol 2009;27:127—145.
  114. van Dalen E.C., Michiels E.M., Caron H.N., Kremer L.C. Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev 2010:CD005006.
  115. Noori A., Lindenfeld J., Wolfel E., et al. Beta-blockade in adriamycin-induced cardiomyopathy. J Card Fail 2000;6:115—119.
  116. Eschenhagen T., Force T., Ewer M.S., et al. Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2011;13:1—10.
  117. Cardinale D., Colombo A., Sandri M.T., et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 2006;114:2474—2481.
  118. Pai V.B., Nahata M.C. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf 2000;22:263—302.
  119. Ayash L.J., Wright J.E., Tretyakov O., et al. Cyclophosphamide pharmacokinetics: correlation with cardiac toxicity and tumor response. J Clin Oncol 1992;10:995—1000.
  120. Mythili Y., Sudharsan P.T., Selvakumar E., Varalakshmi P. Protective effect of DL-alpha-lipoic acid on cyclophosphamide induced oxidative cardiac injury. Chem Biol Interact 2004;151:13—19.
  121. Appelbaum F., Strauchen J.A., Graw R.G. Jr, et al. Acute lethal carditis caused by high-dose combination chemotherapy: a unique clinical and pathological entity. Lancet 1976;1:58—62.
  122. Braverman A.C., Antin J.H., Plappert M.T., et al. Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens. J Clin Oncol 1991;9:1215—1223.
  123. Goldberg M.A., Antin J.H., Guinan E.C., Rappeport J.M. Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor. Blood 1986;68:1114—1118.
  124. Tiersten A., Wo J., Jacobson C., et al. Cardiac toxicity observed in association with high-dose cyclophosphamide-based chemotherapy for metastatic breast cancer. Breast 2004;13:341—346.
  125. Quezado Z.M., Wilson W.H., Cunnion R.E., et al. High-dose ifosfamide is associated with severe, reversible cardiac dysfunction. Ann Intern Med 1993;118:31—36.
  126. Floyd J.D., Nguyen D.T., Lobins R.L., et al. Cardiotoxicity of cancer therapy. J Clin Oncol 2005;23:7685—7696.
  127. Yeh E.T., Tong A.T., Lenihan D.J., et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation 2004;109:3122—3131.
  128. de Forni M., Malet-Martino M.C., Jaillais P., et al. Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study. J Clin Oncol 1992;10:1795—1801.
  129. Jensen S.A., Sørensen J.B. Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine. Cancer Chemother Pharmacol 2006;58:487—493.
  130. Kosmas C., Kallistratos M.S., Kopterides P., et al. Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study. J Cancer Res Clin Oncol 2008;134:75—82.
  131. Dalzell J.R., Samuel L.M. The spectrum of 5-fluorouracil cardiotoxicity. Anticancer Drugs 2009;20:79—80.
  132. Radhakrishnan V., Bakhshi S. 5-Fluorouracil-induced acute dilated cardiomyopathy in a pediatric patient. J Pediatr Hematol Oncol 2011;33:323.
  133. Stewart T., Pavlakis N., Ward M. Cardiotoxicity with 5-fluorouracil and capecitabine: more than just vasospastic angina. Intern Med J 2010;40:303—307.
  134. Basselin C., Fontanges T., Descotes J., et al. 5-Fluorouracil-induced Tako-Tsubo-like syndrome. Pharmacotherapy 2011;31:226.
  135. Grunwald M.R., Howie L., Diaz L.A. Jr. Takotsubo cardiomyopathy and Fluorouracil: case report and review of the literature. J Clin Oncol 2012;30:e11—e14.
  136. de Azambuja E., Bedard P.L., Suter T., Piccart-Gebhart M. Cardiac toxicity with anti-HER-2 therapies: what have we learned so far? Target Oncol 2009;4:77—88.
  137. Sawyer D.B., Zuppinger C., Miller T.A., et al. Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity. Circulation 2002;105:1551—1554.
  138. Force T., Krause D.S., Van Etten R.A. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 2007;7:332—344.
  139. Seidman A., Hudis C., Pierri M.K., et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002;20:1215—1221.
  140. Bird B.R., Swain S.M. Cardiac toxicity in breast cancer survivors: review of potential cardiac problems. Clin Cancer Res 2008;14:14—24.
  141. Telli M.L., Hunt S.A., Carlson R.W., Guardino A.E. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J Clin Oncol 2007;25:3525—3533.
  142. Suter T.M., Procter M., van Veldhuisen D.J., et al. Trastuzumab-associated cardiac adverse effects in the Herceptin Adjuvant Trial. J Clin Oncol 2007;25:3859—3865.
  143. Moja L., Tagliabue L., Balduzzi S., et al. Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev. 2012;4:CD006243.
  144. Procter M., Suter T.M., de Azambuja E., et al. Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial. J Clin Oncol 2010;28:3422—3428.
  145. Wadhwa D., Fallah-Rad N., Grenier D., et al. Trastuzumab mediated cardiotoxicity in the setting of adjuvant chemotherapy for breast cancer: a retrospective study. Breast Cancer Res Treat 2009;117:357—364.
  146. Tarantini L., Cioffi G., Gori S., et al. Trastuzumab adjuvant chemotherapy and cardiotoxicity in real-world women with breast cancer. J Card Fail 2012;18:113—119.
  147. Lenihan D., Suter T., Brammer M., et al. Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab. Ann Oncol 2012;23:791—800.
  148. Gianni L., Lladó A., Bianchi G., et al. Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010;28:1131—1137.
  149. Perez E.A., Koehler M., Byrne J., et al. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc 2008;83:679—686.
  150. Vaklavas C., Lenihan D., Kurzrock R., Tsimberidou A.M. Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target? Oncologist 2010;15:130—141.
  151. Choueiri T.K., Mayer E.L., Je Y., et al. Congestive heart failure risk in patients with breast cancer treated with bevacizumab. J Clin Oncol 2011;29:632—638.
  152. Girardi F., Franceschi E., Brandes A.A. Cardiovascular safety of VEGF-targeting therapies: current evidence and handling strategies. Oncologist 2010;15:683—694.
  153. Zambelli A., Della Porta M.G., Eleuteri E., et al. Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies: novel molecular tools for clinical issues. Breast 2011;20:176—183.
  154. Hawkes E.A., Okines A.F., Plummer C., Cunningham D. Cardiotoxicity in patients treated with bevacizumab is potentially reversible. J Clin Oncol 2011;29:e560—e562.
  155. Chen M.H., Kerkelä R., Force T. Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics. Circulation 2008;118:84—95.
  156. Chu T.F., Rupnick M.A., Kerkela R., et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007;370:2011—2019.
  157. Force T., Kerkelä R. Cardiotoxicity of the new cancer therapeutics: mechanisms of, and approaches to, the problem. Drug Discov Today 2008;13:778—784.
  158. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in meta- static renal-cell carcinoma. N Engl J Med 2007;356:115—124.
  159. Richards C.J., Je Y., Schutz F.A., et al. Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib. J Clin Oncol 2011;29:3450—3456.
  160. Di Lorenzo G., Autorino R., Bruni G., et al. Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis. Ann Oncol 2009;20:1535—1542.
  161. Telli M.L., Witteles R.M., Fisher G.A., Srinivas S. Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Ann Oncol 2008;19: 1613—1618.
  162. Izumiya Y., Shiojima I., Sato K., et al. Vascular endothelial growth factor blockade promotes the transition from compensatory cardiac hypertrophy to failure in response to pressure overload. Hypertension 2006;47:887—893.
  163. Kerkela R., Woulfe K.C., Durand J.B., et al. Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase. Clin Transl Sci 2009;2:15—25.
  164. Wong M.K., Jarkowski A. Response to sorafenib after sunitinib-induced acute heart failure in a patient with metastatic renal cell carcinoma: case report and review of the literature. Pharmacotherapy 2009;29:473—478. 
  165. Maitland M.L., Bakris G.L., Black H.R., et al. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst. 2010;102:596—604. 
  166. Kerkelä R., Grazette L., Yacobi R., et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006;12:908—916.
  167. Trent J.C., Patel S.S., Zhang J., et al. Rare incidence of congestive heart failure in gastrointestinal stromal tumor and other sarcoma patients receiving imatinib mesylate. Cancer 2010;116:184—192.
  168. Moore M.J., Goldstein D., Hamm J., et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960—1966.
  169. Yeh E.T., Bickford C.L. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 2009;53:2231—2247.
  170. Biganzoli L., Cufer T., Bruning P., et al. Doxorubicin-paclitaxel: a safe regimen in terms of cardiac toxicity in metastatic breast carcinoma patients: results from a European Organization for Research and Treatment of Cancer multicenter trial. Cancer 2003;97:40—45.
  171. Martin M., Pienkowski T., Mackey J., et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005;352:2302—2313.
  172. Marty M., Cognetti F., Maraninchi D., et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 Study Group. J Clin Oncol 2005;23:4265—4274.
  173. Palumbo A., Rajkumar S.V., Dimopoulos M.A., et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008;22:414—423.
  174. Gullestad L., Ueland T., Fjeld J.G., et al. Effect of thalidomide on cardiac remodeling in chron- ic heart failure: results of a double-blind, placebo-controlled study. Circulation 2005;112:3408—3414.
  175. Carver J.R., Nasta S., Chong E.A., et al. Myocarditis during lenalidomide therapy. Ann Pharmacother 2010;44:1840—1843.
  176. Thavendiranathan P., Verhaert D., Kendra K.L., Raman S.V. Fulminant myocarditis owing to high-dose interleukin-2 therapy for metastatic melanoma. Br J Radiol 2011;84:e99—e102.
  177. Yao H., He X.H., Bruce I.C., Xia Q. Nitric oxide participates in the negative inotropic effect of interferon-alpha in rat cardiac muscle. Conf Proc IEEE Eng Med Biol Soc 2005;6:5723—5726.
  178. Deyton L.R., Walker R.E., Kovacs J.A., et al. Reversible cardiac dysfunction associated with interferon alfa therapy in AIDS patients with Kaposi’s sarcoma. N Engl J Med 1989;321:1246—1249.
  179. Zimmerman S., Adkins D., Graham M., et al. Irreversible, severe congestive cardiomyopathy occurring in association with interferon alpha therapy. Cancer Biother 1994;9:291—299.
  180. Sonnenblick M., Rosin A. Cardiotoxicity of interferon. A review of 44 cases. Chest 1991;99:557—561.
  181. Tortorella G., Piccin A., Tieghi A., et al. Anagrelide treatment and cardiovascular monitoring in essential thrombocythemia. A prospec- tive observational study. Leuk Res 2015;39:592—598.
  182. Engel P.J., Johnson H., Baughman R.P., Richards A.I. High-output heart failure associated with anagrelide therapy for essential thrombocytosis. Ann Intern Med 2005;143:311—313.
  183. Anagrelide, a therapy for thrombocythemic states: experience in 577 patients: Anagrelide Study Group. Am J Med 1992;92:69—76.
  184. Silverstein M.N., Petitt R.M., Solberg L.A. Jr, et al. Anagrelide: a new drug for treating thrombocytosis. N Engl J Med 1988;318:1292—1294.
  185. Rogers K.C., Oliphant C.S., Finks S.W. Clinical efficacy and safety of cilostazol: a critical review of the literature. Drugs 2015;75:377—395.
  186. Packer M., Carver J.R., Rodeheffer R.J., et al. Effect of oral milrinone on mortality in severe chronic heart failure: the PROMISE Study Research Group. N Engl J Med 1991;325:1468—147.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.